Introduction
Oesophageal cancer (OC) staging uses a multi-modality approach including computed tomography (CT), endoscopic ultrasound (EUS) and positron emission tomography (PET). [1] The additional prognostic value of functional imaging means PET/CT is now routinely used in cancer staging pathways for patients considered suitable for radical therapy. [2] The two most common histological cell types are adenocarcinoma and squamous cell carcinoma (SCC), both of which have a high affinity for 18 F-fluorodeoxyglucose ( 18 F-FDG), making PET particularly useful in OC.
Primary tumour length is commonly reported following upper gastrointestinal (GI) endoscopy, CT, EUS and PET/CT staging investigations.
[3] Of more critical importance is the estimated total length of disease (LoD), defined as the craniocaudal length of primary tumour plus involved regional lymph nodes. Assessment of treatment options, including suitability for definitive chemo-radiotherapy (dCRT), relies on assessment of LoD at staging. A discrepancy in LoD between imaging modalities could affect clinical decision-making and subsequent treatment planning.
Inappropriate radical treatment may be initiated in unsuitable patients, or potentially beneficial therapy could be withheld from those that may respond.
There is now significant interest in the use of PET imaging to assist radiotherapy planning, particularly in OC.
[4] Localisation of the gross tumour volume (GTV) in radiotherapy planning relies on accurate localisation of the LoD. Moreover, there has been a decline in EUS use nationally, making delineation of the GTV more reliant on PET and CT alone. [5] Therefore, this study tested the hypothesis that significant differences exist between PET and EUS LoD. These differences could impact on clinical decision-making and treatment planning, especially in cases where EUS is not performed. The primary aim of this study was to investigate differences in PET and EUS LoD in patients with OC. The secondary aim was to assess the prognostic significance of these measurements.
Materials and Methods

Patient Cohort
Patients staged between January 1 st 2011 and December 31 st 2014 with biopsy proven oesophageal or gastro-oesophageal junction (GOJ) tumours were considered for this study. All EUS examinations were performed by the same operator. In total, 222 patients were considered for inclusion. Exclusion criteria were a non FDG-avid primary tumour (n=30), a tumour too stenotic to be passed with the endoscope (n=13), LoD not recorded in the EUS report (n=18) and patients lost to follow-up (n=1). Following exclusions, 160 patients were included in the study. The institutional review board gave approval for the study (reference 13//DMD5769). Identical viewing settings were used for each case to ensure consistent methodology; the field of view (FOV) was 88.1 cm and the SUV of the MIP display was maintained at 12 g/ml for each case.
Definition of Regional Nodal disease
Regional lymph nodes were defined as any para-oesophageal lymph node from the cervical oesophagus superiorly to the coeliac trunk inferiorly, according to the TNM 7 th edition. [6] Nodes were classed as involved on PET/CT if the node was identified on the CT component and showed FDG uptake appreciably higher than background values. No specific SUV max was used for the inclusion of regional nodes. Lymph nodes not meeting these criteria were considered benign. Non-regional lymph nodes were considered metastatic (M1).
Treatment Planning and Selection
An appropriate individual management plan was selected based on radiological stage, patient choice and relevant comorbidity, according to algorithms used by the Regional Upper GI cancer network. [9, 10] In this study, radiotherapy planning was performed using direct comparison of imaging modalities, considering the maximum LoD recorded. Occasionally, non-deformable fusion of the PET and planning CT was performed, provided the diagnostic PET/CT had been acquired in the radiotherapy planning position to allow accurate fusion.
Survival Data
Overall survival (OS), defined in months survived from the data of diagnosis, was used when assessing the prognostic significance of PET and EUS LoD. Survival data was obtained from the Cancer Network Information Service blinded (blinded, blinded, Wales). All patients were followed up 3-monthly in the first year and 6-monthly thereafter for 5 years, or until death.
Statistical Analysis
Continuous data were expressed as median (range) and categorical data as frequency (percent). A Bland-Altman analysis was used to assess the level of agreement between PET and EUS LoD.
[11] The mean difference (PET minus EUS) and 95% limits of agreement (LA) were calculated. A difference of more than 2 cm between PET and EUS is considered clinically significant for radiotherapy planning, therefore the proportion of cases with a clinically significant difference was also calculated. [12] A non-parametric Wilcoxon signed rank test was used to assess differences between PET and EUS LoD. Univariable survival analysis was performed with the log-rank test according to the life- 
Results
Patient characteristics are detailed in Table 1 A Wilcoxon signed rank test demonstrated a significant difference between PET and EUS LoD (Z= -7.021, p<0.001). EUS LoD was more than 2 cm longer than PET LoD in 61 cases (38.1%). In 8 cases (5.0%), PET LoD was more than 2 cm longer than
Bland-Altman analysis demonstrated substantial variation in measured PET and EUS LoD. (Fig. 3) The mean difference in LoD (PET minus EUS) was -2.2 cm (SD 3.8, 95% LA -9.6 to 5.2). The Bland Altman analysis indicates that the 95% LA between PET and EUS LoD represent a level of disagreement that is potentially clinically significant, suggesting that PET and EUS LoD should not be used interchangeably. (Fig. 4 
Discussion
This study has demonstrated significant differences between PET and EUS LoD in patients with OC. Both PET and EUS LoD were significantly associated with OS on univariable analysis, but were not independent predictors. These results are important for treatment option assessment, which can be complex in OC.
Selection of patients for surgical management, neo-adjuvant treatments or dCRT partly relies on accurate assessment of disease extent, often gained from PET/CT and EUS. The LoD is an important measurement that can influence these decisions.
These results suggest that PET tends to under-measure LoD compared to EUS.
An accepted maximum LoD for consideration of radiotherapy is 10 cm, as described in the SCOPE trial series protocols (17). There is often more concern about length of irradiated volume in the neo-adjuvant setting, leading to a more conservative approach in this scenario. Inaccuracies in LoD estimation could also affect patient selection for neo-adjuvant chemoradiotherapy. [16] In terms of radiotherapy planning, a difference of more than 2 cm between PET and EUS is considered clinically significant. [12] Most modern oesophageal radiotherapy planning protocols allow a margin of 2 cm from GTV to clinical target volume (CTV)
to allow for microscopic spread along the oesophagus. Differences in LoD of more than 2 cm could lead to a significant risk of a geographical miss if the PET measurement is used alone. In this study, up to 38.1% of cases were at risk of a geographical miss. If PET alone is relied upon to guide delineation of GTV, all available diagnostic information, including the upper GI endoscopy report, diagnostic CT and PET/CT images, should be used together to plan radiotherapy. The temptation to outline FDG-avid regions of disease alone should be resisted because it is vital to include disease identified on all available imaging modalities. Usually, the most recent imaging is the radiotherapy planning CT and areas of adjacent, non-avid oesophageal wall thickening should be included in the GTV. This approach is also recommended in the recent SCOPE2 trial radiotherapy planning protocol. [19] EUS assesses local disease more accurately than PET due to its superior contrast and spatial resolution. Submucosal infiltration is also better assessed with EUS. [20] Physiological FDG-uptake in the oesophagus or stomach is often located adjacent to the tumour, creating an 'avidity gradient' which can cause error in measurement.
Another limitation of PET is the suboptimal differentiation of adjacent peri-tumoural lymph node metastases from the primary tumour.
[21] However, PET/CT can add useful information in patients with non-traversable tumours, or in cases where there is involvement of the GOJ. Identification of nodal disease distant to the primary tumour can also be assessed. Overall, these results support the combined use of PET and EUS in radiation treatment planning of OC.
It has been suggested that EUS use should be more focused in OC. EUS is an invasive procedure with risk of serious complications and is operator dependent. In many centres, access to EUS is limited, which can impact on patient pathways and time to treatment. This is supported by evidence that EUS use is declining.
According to the National Oesophago-Gastric Cancer Audit (NOGCA) data, 47.5% of patients with OC had a staging EUS completed in 2016, compared to 62% reported in 2013.
[5] A large single-centre study showed minimal benefit of EUS versus the potential risk of complications in the majority of patients staged T2-T4a on CT.
[22]
The authors suggested that EUS use should be limited to early stage OC and the assessment of resectability in more advanced cases. The additional utility of EUS for accurate radiotherapy planning was not discussed in this paper and should be an additional consideration given the increasing use of neo-adjuvant chemoradiotherapy in recent years.
As for other studies investigating imaging measurements, the true pathological length is unknown, making accurate comparison of different modalities difficult.
Cancer resections specimens can shrink up to 50% in size which is an important consideration when comparing measurements.
[23] Only measurements from single observers for both PET and EUS were analysed in this study, which maintains consistent methodology, but does not allow assessment of inter-observer variability.
Future research should focus on the impact of inter-observer variability on treatment decision-making in patients with OC. Identical settings were used when measuring LoD on the PET MIP images. Some tumours with high intensity variation may not have displayed optimally, which potentially introduced error in measurement.
However, this methodology was adopted to ensure consistency between patients. In addition, the patient population was relatively heterogeneous, which reflects the observational nature of the study. As a result, the patients included in this study received different treatments. Treatment was included in the multi-variable analysis as curative and palliative groups only. Curative therapies were combined as the numbers in some treatment groups were relatively small.
In conclusion, this retrospective study has demonstrated significant differences in measured PET and EUS LoD from OC staging investigations. These measurements showed prognostic significance on univariable analysis but were not independent predictors of survival. Differences in these measurements could potentially impact clinical-decision making and radiotherapy treatment planning. In our view, these results highlight the continued benefit of EUS in the OC staging and treatment pathway, particularly adding information in patients requiring radiotherapy. 
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